Amorphous solid dispersions (ASD) represent a key enabling technology to enhance the dissolu on of poorly soluble drugs and thus ensure sufficient bioavailability and therapeu c effec veness . In its most common form, the drug is molecularly and homogenously dispersed in an amorphous, water-soluble polymer as a glassy solu on, at a defined drug-to-polymer ra o. The polymer can provide mul ple benefits: during storage it inhibits crystalliza on of the drug, while during drug release itself, the polymer both enhances we ability and dissolu on of the drug, and inhibits crystalliza on (spring and parachute effect) . Despite successful examples of amorphous solid dispersions on the market, development of such formula ons is s ll highly challenging, not least due to difficul es in understanding and simultaneously op mizing processability, stability during storage and drug release upon administra on .